Drug Use Investigation for TYKERB Tablet (All Case Investigation)
NCT01332396 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4054
Last updated 2017-04-26
Summary
Data on the safety and efficacy of TYKERB shall be collected from the patients in order to grasp the actual conditions of post-marketing use and assess background information on the patients.
Conditions
Interventions
- DRUG
-
Lapatinib
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-06-30
- Primary Completion
- 2017-03-13
- Completion
- 2017-03-13
More Related Trials
-
Clinical Trial for Effect of TQB3616 Capsule on Pharmacokinetics in Healthy Adult Subjects
NCT05344729 ·Status: COMPLETED ·Phase: PHASE1
-
Statin Therapy in Young Adult Survivors of Childhood Cancer
NCT01733953 ·Status: COMPLETED ·Phase: PHASE2
-
A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
NCT01328054 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors
NCT00570284 ·Status: COMPLETED ·Phase: PHASE1
-
Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors
NCT00972205 ·Status: COMPLETED ·Phase: NA
-
Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
NCT01030055 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Study of Intrathecal Topotecan
NCT00001333 ·Status: COMPLETED ·Phase: PHASE1
-
Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer
NCT04298333 ·Status: COMPLETED ·Phase: PHASE1
-
To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients
NCT00258050 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors
NCT01155713 ·Status: COMPLETED ·Phase: PHASE1
-
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
NCT00158782 ·Status: COMPLETED ·Phase: PHASE1
-
Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function
NCT00002901 ·Status: COMPLETED ·Phase: PHASE1
-
Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype
NCT05691400 ·Status: WITHDRAWN ·Phase: PHASE4
-
A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors
NCT00682279 ·Status: WITHDRAWN ·Phase: PHASE1
-
TICOP Mobile App and E-platform: Providing Information and Support for Parents Caring for Their Child Cancer Survivor
NCT03945032 ·Status: WITHDRAWN ·Phase: NA
-
Open-Label Extension and Safety Study of Talazoparib
NCT02921919 ·Status: COMPLETED ·Phase: PHASE2
-
Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast Cancer
NCT06367335 ·Status: COMPLETED
-
Pharmacometabolomic of Trabectedin in Soft Tissue Patients
NCT04394728 ·Status: COMPLETED
-
Oral Docetaxel in Patients With Normal or Impaired Liver Function
NCT05084456 ·Status: WITHDRAWN ·Phase: PHASE1
-
Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer
NCT00982566 ·Status: COMPLETED ·Phase: PHASE1
-
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
NCT05251714 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
The Role of Calcipotriol as Radioprotector of Skin
NCT00445250 ·Status: UNKNOWN ·Phase: PHASE2
-
A Clinical Trial of TQB3454 Tablets in Healthy Adult Subjects
NCT06139367 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
NCT06377852 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies
NCT03338881 ·Status: WITHDRAWN ·Phase: PHASE1